• 1
    In Ries LAG, Smith MA, Gurney JG, et al. (eds). Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. Bethesda, MD: National Cancer Institute, SEER Program; 1999. NIH Pub. No. 99-4649.
  • 2
    American Cancer Society. Cancer facts & figures 2011. Atlanta: American Cancer Society; 2011.
  • 3
    Redaelli A, Bell C, Casagrande J, et al. Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev Anticancer Ther 2004; 4:8596.
  • 4
    Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukemia. The Lancet 2007; 370:342350.
  • 5
    Kantarjian H. Price of drugs for chronic myeloid leukemia (CML), reflection of the unsustainable cancer drug prices: perspective of CML experts. Blood 2013; doi: 10.1182/blood-2013-03-490003.
  • 6
    Kanavos P, Vandoros S, Garcia-Gonzalez P. Benefits of global partnerships to facilitate access to medicines in developing countries: A multi-country analysis of patients and patient outcomes in GIPAP. Global Health 2009; 5:19.
  • 7
    Mendizabal AM, Garcia-Gonzalez P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol 2013; 37:247254.
  • 8
    Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a Children's Oncology Group phase 1 study. Blood 2001; 104:26552660.
  • 9
    United Nations, World Macro Regions and Components [Internet]; 2009; 450 [accessed 15.05.09].
  • 10
    Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Incidence - SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub, (1973–2009).
  • 11
    Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int 494 J Hematol 2009; 89:1423.
  • 12
    Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely effects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011; 86:471474.
  • 13
    Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes 478 of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 2009; 113:54015411.
  • 14
    Narayanan KR1, Bansal D, Walia R, et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer 2013; 60:11481153.
  • 15
    Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol 2009; 27:51755181.
  • 16
    Andolina JR1, Neudorf SM, Corey SJ. How I treat childhood CML. Blood 2012; 119:18211830.
  • 17
    Millot F, Baruchel A, Guilhot J, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J Clin Oncol 2011; 29:28272832.
  • 18
    American Cancer Society. Global cancer facts & figures, 2nd edition. Atlanta: American Cancer Society; 2011. Available at
  • 19
    Kachroo S1, Etzel CJ. Decreasing the cancer burden in developing countries: Concerns and recommendations. Eur J Cancer Care 2009; 18:1821.
  • 20
    World Health Organization (WHO). 2007a; Cancer: Diet and physical activity's impact. Available at: